HIV感染对炎症性肠病病程及药物安全性的影响:多中心GETAID研究
这项多中心回顾性队列研究纳入65例HIV感染的IBD患者并按1:2匹配130例无HIV感染者,发现HIV感染组免疫抑制剂和生物制剂使用率显著更低,但CD和UC的疾病严重复合终点无显著差异,总体药物安全性相似。提示HIV感染可能减轻IBD活动,药物安全性令人放心。
要点
- HIV感染IBD患者免疫抑制剂和生物制剂使用率显著低于无HIV感染者。
- HIV感染组与无HIV感染组的CD和UC疾病严重复合终点无显著差异。
- 两组总体药物安全性相似,可按现行推荐治疗HIV合并IBD患者。
核心结论
- HIV感染患者虽接受更少治疗,但IBD病程与未感染者无差异,提示HIV感染可能减轻IBD。
- 药物安全性总体相似且令人放心,允许医生按现行推荐治疗此类患者。
研究设计与样本
- 多中心回顾性队列研究,2019年1月至2020年8月纳入所有成年IBD合并HIV感染患者。
- 每例HIV感染IBD患者按1:2匹配无HIV感染的IBD患者。
- 共纳入195例IBD患者,其中65例HIV感染,130例无HIV感染。
主要发现
- 65例HIV感染患者中22例(33.8%)需要免疫抑制剂,31例(47.7%)需要生物制剂。
- HIV感染组免疫抑制剂需求显著更低:CD p=0.034,UC p=0.012。
- HIV感染组生物制剂需求显著更低:CD p=0.004,UC p=0.008。
- 疾病严重复合终点无显著差异:CD HR=1.3 [0.7; 2.4],p=0.45;UC HR=1.1 [0.5; 2.7],p=0.767。
- 两组总体药物安全性统计相似。
临床怎么用
- HIV合并IBD患者可按现行推荐接受免疫抑制剂和生物制剂治疗,药物安全性令人放心。
- HIV感染可能减轻IBD活动,临床评估时应考虑此因素。
局限性
- 回顾性队列设计可能存在选择偏倚和信息偏倚。
- 样本量较小(65例HIV感染患者),可能影响统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), and human immunodeficiency virus (HIV) both impact innate and adaptive immunity in the intestinal mucosa. As it is a rare situation, the intersection between HIV and IBD remains unclear, especially the impact of HIV infection on the course of IBD, and the drug safety profile is unknown. METHODS: We conducted a multicenter retrospective cohort study between January 2019 and August 2020. All adult patients with IBD and concomitant HIV infection were included. Each IBD patient with HIV was matched to two HIV-uninfected IBD patients. RESULTS: Overall, 195 patients with IBD were included, including 65 HIV-infected patients and 130 without HIV infection. Of the 65 infected patients, 22 (33.8%) required immunosuppressants and 31 (47.7%) biologics. In the HIV-infected group, the need for immunosuppressants (p = 0.034 for CD and p = 0.012 for UC) and biologics (p = 0.004 for CD and p = 0.008 for UC) was significantly lower. The disease course, using a severity composite criterion, was not significantly different between the two groups for CD (hazard ration (HR) = 1.3 [0.7; 2.4], p = 0.45) and UC (HR, 1.1 [0.5; 2.7], p = 0.767). The overall drug safety profile was statistically similar between the two groups. CONCLUSION: Although HIV-infected patients receive less treatments, the course of their IBD did not differ than uninfected, suggesting that HIV infection might attenuate IBD. The drug safety profile is reassuring, allowing physician to treat these patients according to current recommendations.
引用
- Guillo L, Uzzan M, Beaugerie L, et al. Impact of HIV Infection on the Course of Inflammatory Bowel Disease and Drug Safety Profile: A Multicenter GETAID Study. Clin Gastroenterol Hepatol. 2020. PMID: 33359726. doi:10.1016/j.cgh.2020.12.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。